Target specificity of selective estrogen receptor modulators within human endometrial cancer cells

被引:30
|
作者
Bramlett, KS [1 ]
Burris, TP [1 ]
机构
[1] Lilly Corp Ctr, Lilly Res Labs, Gene Regulat & Bone Res, Indianapolis, IN 46285 USA
关键词
nuclear receptor; SERM; lasofoxifene; coactivator; raloxifene; ALKALINE-PHOSPHATASE ACTIVITY; CONFORMATIONAL-CHANGES; GENE-EXPRESSION; ER BETA; COACTIVATOR; BINDING; ANTIESTROGEN; AGONIST; ALPHA; PROLIFERATION;
D O I
10.1016/S0960-0760(03)00258-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Selective estrogen receptor modulators (SERMs) are estrogen receptor (ER) ligands that function as antagonists in some tissues, but have either partial or full agonist activity in others. SERMs often display variable partial agonist activity in uterine tissues and this activity can be displayed in uterine cell lines such as the human Ishikawa endometrial adenocarcinoma cell line. In this study, we compared the effects of several ER ligands including some SERMs on alkaline phosphatase (AP) activity and the expression of an ER target gene, the progesterone, receptor (PR), in Ishikawa cells. As expected, estradiol (E2) was a potent and efficacious activator of both AP activity and PR mRNA expression. 4-Hydroxytamoxifen (4OHT) stimulated AP activity to a level 47% of that of E2 (100 nM), while CP 336156 (lasofoxifene) increased AP activity 18%. A benzothiophene, such as LY 117018, a raloxifene analog, stimulated AP even less with values approximately 11% of E2-stimulated levels. A pure antiestrogen, ICI 182,780 did not stimulate AP activity. Interestingly, when we examined the ability of these compounds to increase the expression of the ER target gene, PR, a different rank order of efficacy was detected. After E2, CP 336156 was the most efficacious in increasing PR mRNA with a maximal stimulation of 20% of E2 levels, while 4OHT stimulated only 17%. LY 117018 increased PR mRNA expression 8% while ICI 182,780 did not increase PR mRNA expression at all. These data illustrate the target specificity that a SERM is able to display within a single cell type independent of "tissue specificity" and differential levels of expression of various cofactors. While 4OHT is 160% more active than CP 336156 in terms of inducing AP activity in the Ishikawa cells. CP 336156 has equivalent activity as 4OT when one examines the ability of these SERMs to induce PR mRNA expression. Since the stimulation of Ishikawa cells by ER ligands is often used to assess the potential in vivo uterotrophic activity, these data indicate that examination of several endpoints in these cells may be necessary in order to fully characterize the activity of SERMs. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 50 条
  • [21] Minireview: Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?
    Lupu, Ruth
    Menendez, Javier A.
    ENDOCRINOLOGY, 2006, 147 (09) : 4056 - 4066
  • [22] The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer
    Howell, SJ
    Johnston, SRD
    Howell, A
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 18 (01) : 47 - 66
  • [23] Estrogen and selective estrogen receptor modulators regulate vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in human endometrial stromal cells
    Okada, Hidetaka
    Tsutsumi, Akihiro
    Imai, Miyuki
    Nakajima, Tatsuya
    Yasuda, Katsuhiko
    Kanzaki, Hideharu
    FERTILITY AND STERILITY, 2010, 93 (08) : 2680 - 2686
  • [24] Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β
    Tee, MK
    Rogatsky, I
    Tzagarakis-Foster, C
    Cvoro, A
    An, JP
    Christy, RJ
    Yamamoto, KR
    Leitman, DC
    MOLECULAR BIOLOGY OF THE CELL, 2004, 15 (03) : 1262 - 1272
  • [25] Estrogen receptor cofactors expression in breast and endometrial human cancer cells
    Thenot, S
    Charpin, M
    Bonnet, S
    Cavailles, V
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1999, 156 (1-2) : 85 - 93
  • [26] The Effect of Selective Estrogen Receptor Modulators (SERMs) on the Tamoxifen Resistant Breast Cancer Cells
    Bo Yoon Chang
    Sae Am Kim
    Bindu Malla
    Sung Yeon Kim
    Toxicological Research, 2011, 27 (2) : 85 - 93
  • [27] The Effect of Selective Estrogen Receptor Modulators (SERMs) on the Tamoxifen Resistant Breast Cancer Cells
    Chang, Bo Yoon
    Kim, Sae Am
    Malla, Bindu
    Kim, Sung Yeon
    TOXICOLOGICAL RESEARCH, 2011, 27 (02) : 85 - 93
  • [28] Breast cancer prevention with selective estrogen receptor modulators - A perspective
    Pritchard, KI
    SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS), 2001, 949 : 89 - 98
  • [29] Selective estrogen receptor modulators and prevention of invasive breast cancer
    Gradishar, WJ
    Cella, D
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (23): : 2784 - 2786
  • [30] Recent Advances in Selective Estrogen Receptor Modulators for Breast Cancer
    Wang, Tianlin
    You, Qidong
    Huang, Frank Shu-gui
    Xiang, Hua
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2009, 9 (10) : 1191 - 1201